Comparing the efficacy of Delta-Tocotrienol and resveratrol mixture vs placebo on reducing the cardiometabolic risk and associated biochemical markers in patients with Metabolic Syndrome – A Randomized Controlled Trial - Trial SLCTR_2019_021
Access comprehensive clinical trial information for SLCTR_2019_021 through Pure Global AI's free database. This Phase 2 trial is sponsored by AFIP / National University of Medical Sciences and is currently status unknown. The study focuses on Metabolic Syndrome.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
SLCTR_2019_021
Phase 2
Trial Details
Sri Lanka Clinical Trials Registry • SLCTR_2019_021
Comparing the efficacy of Delta-Tocotrienol and resveratrol mixture vs placebo on reducing the cardiometabolic risk and associated biochemical markers in patients with Metabolic Syndrome – A Randomized Controlled Trial
Effects of Delta-tocotrienol and Resveratrol Supplementation on Cardiometabolic Risk Factors, Biochemical Markers and microRNAs in Patients with Metabolic Syndrome
Study Focus
Interventional
Sponsor & Location
AFIP / National University of Medical Sciences
Pakistan
Timeline & Enrollment
Phase 2
N/A
N/A
ICD-10 Classifications
Metabolic disorders
Metabolic disorder, unspecified
Other metabolic disorders
Other specified metabolic disorders
Nutritional and metabolic disorders in diseases classified elsewhere
Data Source
Sri Lanka Clinical Trials Registry
SLCTR_2019_021
Non-Device Trial